新型冠状病毒肺炎抗病毒治疗。

Antiviral Treatment of Coronavirus Disease-2019 Pneumonia.

机构信息

Section of Infectious Diseases, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA.

Section of Infectious Diseases, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.

出版信息

Clin Chest Med. 2023 Jun;44(2):279-297. doi: 10.1016/j.ccm.2022.11.008. Epub 2022 Nov 28.

DOI:10.1016/j.ccm.2022.11.008

PMID:37085220

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9701636/

Abstract

Direct acting antivirals and monoclonal antibodies reduce morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 infection. Persons at higher risk for disease progression and hospitalized patients with coronavirus disease-2019 (COVID-19) benefit most from available therapies. Following an emphasis on inpatient treatment of COVID-19 during the early pandemic, several therapeutic options were developed for outpatients with COVID-19. Additional clinical trials and real-world studies are needed to keep pace with the evolving pandemic.

摘要

直接作用抗病毒药物和单克隆抗体可降低与严重急性呼吸综合征冠状病毒 2 感染相关的发病率和死亡率。疾病进展风险较高的人群和患有 2019 冠状病毒病（COVID-19）的住院患者从可用的治疗方法中获益最大。在大流行早期强调对 COVID-19 的住院治疗后，为 COVID-19 门诊患者开发了几种治疗选择。需要开展更多的临床试验和真实世界研究，以跟上不断演变的大流行形势。